An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease

Journal of Allergy and Clinical Immunology

Volumn 121, Issue 1, 2008, Pages 81-87

  Shaker, Marcus ^a,b   Lobb, Ano ^b   Jenkins, Pamela ^a   O'Rourke, Daniel ^a   Takemoto, Steve K ^c   Sheth, Salil ^c   Burroughs, Thomas ^c   Dykewicz, Mark S ^d  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b Dartmouth's Center for the Evaluative Clinical Sciences   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Department of Internal Medicine   (United States)

Author keywords

aspirin desensitization; aspirin exacerbated respiratory disease; Cost effectiveness analysis; quality adjusted life year

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CLOPIDOGREL; CORTICOSTEROID; LEUKOTRIENE; STEROID;

ADULT; ARTICLE; ASPIRIN EXACERBATED RESPIRATORY DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DESENSITIZATION; DRUG HYPERSENSITIVITY; ECONOMICS; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HEART INFARCTION; HUMAN; INTERVENTION STUDY; MEDICAL LITERATURE; PRIORITY JOURNAL; PROBABILITY; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; RESPIRATORY TRACT DISEASE; STROKE; SYMPTOM;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; ASTHMA; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; HUMANS; MARKOV CHAINS; MIDDLE AGED; MODELS, BIOLOGICAL; PLATELET AGGREGATION INHIBITORS; QUALITY-ADJUSTED LIFE YEARS; RESPIRATION DISORDERS; TICLOPIDINE;

EID: 38149135636     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2007.06.047     Document Type: Article

References (42)

1. Centers for Disease Control and Prevention. National Center for Environmental Health, Behavioral Risk Factor Surveillance System 2004 prevalence data. Available at: http://www.cdc.gov/asthma/brfss/04/brfssdata.htm#lc. Accessed March 8, 2007.
2. Jenkins C., Costello J., and Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 328 (2004) 434
3. McDonald J.R., Mathison D.A., and Stevenson D.D. Aspirin intolerance in asthma. Detection by oral challenge. J Allergy Clin Immunol 50 (1972) 198-207
4. Kasper L., Sladek K., Duplaga M., Bochenek G., Liebhart J., Gladysz U., et al. Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy 58 (2003) 1064-1066
5. Mascia K., Haselkorn T., Deniz Y.M., Miller D.P., Bleecker E.R., and Borish L. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 116 (2005) 970-975
6. Berges-Gimeno M.P., Simon R.A., and Stevenson D.D. Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 90 (2003) 338-341
7. Berges-Gimeno M.P., Simon R.A., and Stevenson D.D. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 111 (2003) 180-186
8. Gosepath J., Schafer D., and Mann W.J. [Aspirin sensitivity: long term follow-up after up to 3 years of adaptive desensitization using a maintenance dose of 100 mg of aspirin a day]. Laryngorhinootologie 81 (2002) 732-738
9. Gollapudi R.R., Teirstein P.S., Stevenson D.D., and Simon R.A. Aspirin sensitivity: implications for patients with coronary artery disease. JAMA 292 (2004) 3017-3023
10. Ramanuja S., Breall J.A., and Kalaria V.G. Approach to "aspirin allergy" in cardiovascular patients. Circulation 110 (2004) e1-e4
11. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
12. Schaefer O.P., and Gore J.M. Aspirin sensitivity: the role for aspirin challenge and desensitization in postmyocardial infarction patients. Cardiology 91 (1999) 8-13
13. Silberman S., Neukirch-Stoop C., and Steg P.G. Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. Am J Cardiol 95 (2005) 509-510
14. Gaspoz J.M., Coxson P.G., Goldman P.A., Williams L.W., Kuntz K.M., Hunink M.G., et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 346 (2002) 1800-1806
15. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348 (1996) 1329-1339
16. Hunink M.G. Decision making in health and medicine: integrating evidence and values (2004), Cambridge University Press, Cambridge (United Kingdom)
17. Winkelmayer W.C., Weinstein M.C., Mittleman M.A., Glynn R.J., and Pliskin J.S. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 22 (2002) 417-430
18. Drugstore.com online pharmacy. Available at: http://www.drugstore.com/. Accessed March 6, 2006.
19. Murphy M.P., Fishman P., Short S.O., Sullivan S.D., Yueh B., and Weymuller Jr. E.A. Health care utilization and cost among adults with chronic rhinosinusitis enrolled in a health maintenance organization. Otolaryngol Head Neck Surg 127 (2002) 367-376
20. Ray N.F., Baraniuk J.N., Thamer M., Rinehart C.S., Gergen P.J., Kaliner M., et al. Healthcare expenditures for sinusitis in 1996: contributions of asthma, rhinitis, and other airway disorders. J Allergy Clin Immunol 103 (1999) 408-414
21. Ray N.F., Baraniuk J.N., Thamer M., Rinehart C.S., Gergen P.J., Kaliner M., et al. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. J Allergy Clin Immunol 103 (1999) 401-407
22. HCUPnet, Healthcare Cost and Utilization Project. Rockville (MD): Agency for Healthcare Research and Quality. Available at: http://www.ahrq.gov/HCUPnet/. Accessed June 6, 2005.
23. Bureau of Labor Statistics. Available at: http://www.bls.gov/. Accessed March 10, 2006.
24. National Center for Health Statistics Life Tables. Available at: http://www.cdc.gov/nchs/products/pubs/pubd/lftbls/life/1966.htm. Accessed March 6, 2006.
25. Spector S., Bernstein I., Li J., Berger W., Kaliner M., Schuller D., et al. Parameters for the diagnosis and management of sinusitis. J Allergy Clin Immunol 102 suppl (1998) S107-S144
26. Boudreaux E.D., Emond S.D., Clark S., and Camargo Jr. C.A. Acute asthma among adults presenting to the emergency department: the role of race/ethnicity and socioeconomic status. Chest 124 (2003) 803-812
27. Wong J.T., Nagy C.S., Krinzman S.J., Maclean J.A., and Bloch K.J. Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema. J Allergy Clin Immunol 105 (2000) 997-1001
28. Yuval R., Halon D., and Lewis B. Perceived disability and lifestyle modification following hospitalization for non-ST elevation versus ST elevation acute coronary syndromes: the patients' point of view. Eur J Cardiovasc Nurs (2007)
29. Ridker P.M., Cook N.R., Lee I.M., Gordon D., Gaziano J.M., Manson J.E., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352 (2005) 1293-1304
30. Blumenschein K., and Johannesson M. Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma. Ann Allergy Asthma Immunol 80 (1998) 189-194
31. Mittmann N., Trakas K., Risebrough N., and Liu B.A. Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics 15 (1999) 369-376
32. Bradley C.J., Kroll J., and Holmes-Rovner M. The health and activities limitation index in patients with acute myocardial infarction. J Clin Epidemiol 53 (2000) 555-562
33. Zillich A.J., Blumenschein K., Johannesson M., and Freeman P. Assessment of the relationship between measures of disease severity, quality of life, and willingness to pay in asthma. Pharmacoeconomics 20 (2002) 257-265
34. White A.A., Stevenson D.D., and Simon R.A. The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 95 (2005) 330-335
35. Stevenson D.D., and Simon R.A. Selection of patients for aspirin desensitization treatment. J Allergy Clin Immunol 118 (2006) 801-804
36. Settipane R.A., and Stevenson D.D. Cross sensitivity with acetaminophen in aspirin-sensitive subjects with asthma. J Allergy Clin Immunol 84 (1989) 26-33
37. Jenkins C. Recommending analgesics for people with asthma. Am J Ther 7 (2000) 55-61
38. Tan K., Sulke N., Taub N., and Sowton E. Clinical and lesion morphologic determinants of coronary angioplasty success and complications: current experience. J Am Coll Cardiol 25 (1995) 855-865
39. Popma J.J., Berger P., Ohman E.M., Harrington R.A., Grines C., and Weitz J.I. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 suppl (2004) 576S-599S
40. Leon M.B., Baim D.S., Popma J.J., Gordon P.C., Cutlip D.E., Ho K.K., et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 339 (1998) 1665-1671
41. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., and Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
42. Diener H.C., Bogousslavsky J., Brass L.M., Cimminiello C., Csiba L., Kaste M., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364 (2004) 331-337